Germany restricts Bromidia dispensing and bans public advertising

From 1 October 1907, German rules on proprietary medicines subjected Battle & Co.’s Bromidia to both written-order dispensing controls and a public advertising prohibition. The contemporary pharmaceutical journal reproduces the Federal Council’s resolution of 27 June 1907, including its commencement clause and product schedules.

This is evidence of regulation of a named commercial medicine associated with cannabis. It does not establish a prohibition of cannabis medicines as a class.

The decisive product listing

Bromidia appears as item 9 in Anlage B, printed on page 280 of the fourth annual volume of the Vierteljahresschrift für praktische Pharmazie. Section 3, on page 277, requires medicines in this schedule to be dispensed only on a written order bearing a date and signature from a physician, dentist or veterinarian, with veterinary orders restricted to animal use.

Every repeat dispensing required a renewed order. Packaging for medicines subject to medical-order dispensing also had to carry a corresponding notice. These provisions establish more than a warning about undesirable advertising.

Restrictions on promotion and packaging

Section 4 prohibited public announcements and promotion of products in either schedule. It also covered public notices directing readers to publications or other communications promoting those products.

Section 2 imposed identifying information on containers and outer packaging, including the medicine and manufacturer, with further retail identification and price information. It prohibited promotional claims on the packaging or their distribution with the medicine, including endorsements and statements attributing healing or protective effects.

Section 1 prevented simple renaming from avoiding the rules where the composition remained substantially unchanged. Section 5 set commencement at 1 October 1907, replacing the earlier announcement of July 1903. Section 6 specified fines up to 150 marks or corresponding detention.

The journal adds on page 281 that substantially corresponding ordinances had been issued in the constituent states. This supports recording the coordinated German measure; it does not supply the individual text or enforcement record of every state ordinance.

What the cannabis connection establishes

The American Medical Association’s 1914 report reproduces Bromidia advertising and labels referring to cannabis indica. It also questions how much cannabis remained in the finished medicine and discusses changes in the way its composition was declared. That later evidence helps explain the product’s cannabis association, but cannot prove identical content in every bottle sold in Germany in 1907.

The regulation itself names Bromidia without stating its ingredients or attributing the restriction specifically to cannabis. The entry therefore records branded-medicine controls, with the composition uncertainty stated, and leaves Germany’s existing historical score allocations unchanged.^[1][2]